Zepzelca Alternatives Compared
Zepzelca (lurbinectedin) | Etoposide | Imfinzi (durvalumab) |
|
---|
Zepzelca (lurbinectedin) | Etoposide | Imfinzi (durvalumab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Small Cell Lung Cancer. Zepzelca may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Small Cell Lung Cancer, Testicular Cancer, Hodgkin's Lymphoma, Ovarian Cancer, Cancer, Multiple Myeloma. Etoposide may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Biliary Tract Tumor, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Endometrial Cancer. Imfinzi may also be used for purposes not listed in this medication guide. View more |
Related suggestions Small Cell Lung Cancer
|
|||||||||||||||||||||||
More about Zepzelca (lurbinectedin) | More about Etoposide | More about Imfinzi (durvalumab) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
Imfinzi has an average rating of 8.7 out of 10 from a total of 6 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
N/A |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Zepzelca prices |
View all Etoposide prices |
View all Imfinzi prices |
||||||||||||||||||||||||
Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
N/A |
Etopophos, Toposar |
N/A |
||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
51 hours |
11 hours |
408 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 434 drugs are known to interact with Zepzelca:
|
A total of 447 drugs are known to interact with Etoposide:
|
A total of 438 drugs are known to interact with Imfinzi:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
N/A |
December 30, 1986 |
May 01, 2017 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.